$250.59
-0.41-0.16%
At close: -
$250.59
0.000.00%
After Hours: 4:11 PM EDT
Alnylam Pharmaceuticals reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Alnylam Pharmaceuticals using advanced sorting and filters.
Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Q4 | 2025-02-13 | $0.06 | $-0.14 | 142.9 % |
Q3 | 2024-10-31 | $-0.50 | $-0.93 | 46.2 % |
Q2 | 2024-08-01 | $0.56 | $-1.08 | 151.8 % |
Q1 | 2024-05-02 | $-0.16 | $-1.18 | 86.4 % |
Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Q4 | 2025-02-13 | $593.17M | $580.62M | 2.16 % |
Q3 | 2024-10-31 | $500.92M | $533.10M | -6.04 % |
Q2 | 2024-08-01 | $659.83M | $444.11M | 48.6 % |
Q1 | 2024-05-02 | $494.33M | $427.33M | 15.7 % |
Alnylam Pharmaceuticals (ALNY) is scheduled to report earnings on May 1, 2025. The last reported earnings were for reported on February 13, 2025 for Q4.
The Actual EPS was $0.06, which beat the estimate of $-0.14.
The Actual Revenue was $593.2M, which beat the estimate of $580.6M.
Browse earnings estimates, EPS, and revenue on all stocks.